What we have achieved.
Our tradition of innovations is long. We have been inventing therapeutic solutions for the unmet needs of patients and healthcare providers for more than 117 years, always following the principle of our founder Friedrich Merz: “Do it differently than the others.”
In order to meet patients’ needs even better and to reach even more people by driving responsible growth, Merz Therapeutics, part of the Merz Group, has been operating as an individual business since 2020.
At a glance
History of therapeutic innovations
Acquisition of commercial medicines from Acorda Therapeutics
Merz acquires two commercial medicines from Acorda Therapeutics for treatment of Parkinson’s disease and multiple sclerosis
Multiple approvals in Asia and Europe
- Merz’s partner in Japan, Teijin Pharma, receives approval for a treatment of lower limb spasticity in adults
- Merz receives EU approval for a treatment of chronic sialorrhea due to neurological / neurodevelopmental disorders in children and adolescents age 2 to 17
- Merz and Israeli start-up Vensica launch strategic partnership for a treatment of overactive bladder
Multiple approvals in Asia and the US
- Merz’s partner in Japan, Teijin Pharma, receives approval for a treatment of upper limb spasticity in adults
- Merz receives US approval for a treatment of upper limb spasticity in children age 2 to 17, excluding spasticity caused by cerebral palsy
- Merz receives US approval for a treatment of chronic sialorrhea in patients age 2 and older
Start of Merz Therapeutics as a standalone business
Start of Merz Therapeutics as a dedicated company within the Merz Group committed to serving the unmet needs of patients suffering from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life
Multiple approvals in the EU and US
- Merz receives US approval for first-line treatment of blepharospasm in adults
- Merz receives EU approval for a treatment of chronic sialorrhea and symptomatic treatment of hemifacial spasm in adults
US approval of chronic sialorrhea treatment
Merz receives US approval for a treatment of chronic sialorrhea in adults
US approval of upper limb spasticity treatment
Merz receives US approval for a treatment of upper limb spasticity in adults
Launch of treatment for vocal fold insufficiency
Merz launches a treatment for vocal fold insufficiency, providing both short-term and long-term options for patients in a single portfolio
US approval of chronic severe drooling treatment
Merz receives US approval for a treatment of chronic severe drooling in children with neurological conditions
US approval of cervical dystonia and blepharospasm treatment
Merz receives US approval for a treatment of cervical dystonia and blepharospasm in adults who have been pre-treated
EU approval of post-stroke spasticity treatment
Merz receives EU approval for a treatment of post-stroke upper limb spasticity in adults
German approval of blepharospasm and cervical dystonia treatment
Merz receives German approval for a treatment of blepharospasm and cervical dystonia in adults
Launch of treatment for Alzheimer’s disease
Merz launches a treatment for moderate to severe Alzheimer’s disease
Launch of treatment for diffuse hair loss and nail growth disorders
Merz launches a treatment for various forms of diffuse hair loss and improvement in hair growth, hair damaged by sunlight and UV radiation, and nail growth disorders
Launch of treatment for symptoms of Parkinson’s disease
Marked Merz’ entry into the field of neurology with a treatment for symptoms of Parkinson’s disease, such as rigor, tremor and hypo or akinesia, drug-induced extrapyramidal symptoms such as early dyskinesia, akathisia, and parkinsonoid syndrome
Launch of treatment for chronic liver diseases with insufficient hepatic detoxification
Marked Merz’s entry into the field of hepatology with a treatment of chronic liver diseases with insufficient hepatic detoxification (e.g. in liver cirrhosis) and its complications (hepatic encephalopathy)
Launch of treatment for scar prevention and wound healing
Marked Merz’s entry into the field of dermatology with a treatment for prevention of scars, for fresh or older scars and keloids, promoting the normal wound healing process, anti-inflammatory, anti-redness, reducing swelling, pain and irritation
M-NON-NOC-0002 October 2025
